Synapse - Works

Results (5250)

Outcomes of allogeneic hematopoietic stem cell transplant in patients with cerebral adrenoleukodystrophy vary by donor cell source, conditioning regimen, and stage of cerebral disease status

Meeting Abstract

Boelens, J. J.; Chiesa, R.; Duncan, C.; Jones, S.; Kapoor, N.; Kuhl, J. S.; Lindemans, C.; Prasad, V. K.; Sevin, C.; Shamir, E.; more...
Bone Marrow Transplantation (2020)

Fulltext@MSK | Save

Population pharmacokinetic estimation of ATG exposure predicts immune reconstitution and survival in adults undergoing ex vivo CD34-selected allogeneic hematopoietic cell transplantation

Meeting Abstract

Scordo, M.; Cho, C.; Devlin, S. M.; Maloy, M. A.; Ruiz, J. D.; Bhatt, V.; Smith, M.; O'Reilly, R. J.; Papadopoulos, E. B.; Jakubowski, A. A.; more...
Bone Marrow Transplantation (2020)

Fulltext@MSK | Save

Rabbit anti-thymocyte globulin (ATG) exposure after ex vivo T-cell-depleted hematopoietic cell transplantation is variable and impacts immune reconstitution and survival in children and young adults

Meeting Abstract

Lakkaraja, M.; Mauguen, A.; Boulad, F.; Spitzer, B.; Scaradavou, A.; Curran, K.; Cancio, M.; Roessel, I.; Klein, E.; Kernan, N.; more...
Bone Marrow Transplantation (2020)

Fulltext@MSK | Save

Baseline immune status predicts response to adoptive therapy with CMV CTLS for refractory CMV

Meeting Abstract

Fabrizio, V.; Rodriguez-Sanchez, I.; Mauguen, A.; Dahi, P.; Doubrovina, E.; O'Reilly, R. J.; Prockop, S.
Bone Marrow Transplantation (2020)

Fulltext@MSK | Save

Efficacy and updated safety results from pivotal phase II trial 201 of naxitamab (Hu3F8): A humanized GD2-targeted immunotherapy for the treatment of refractory/relapsed (R/R) high-risk (HR) neuroblastoma (NB)

Meeting Abstract

Mora, J.; Chan, G. C.; Morgenstern, D. A.; Nysom, K.; Bear, M.; Worsaae Dalby, L.; Lisby, S.; Kushner, B. H.
Annals of Oncology (2020)

Fulltext@MSK | Save

Pivotal trial 201 data on outpatient administration of naxitamab (Hu3F8), a humanized GD2 targeted immunotherapy for the treatment of refractory/relapsed (R/R) high-risk (HR) neuroblastoma (NB)

Meeting Abstract

Morgenstern, D. A.; Mora, J.; Chan, G. C.; Nysom, K.; Bear, M.; Worsaae Dalby, L.; Lisby, S.; Kushner, B. H.
Annals of Oncology (2020)

Fulltext@MSK | Save

A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents, and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082)

Meeting Abstract

Gaspar, N.; Campbell-Hewson, Q.; Bielack, S. S.; Campbell, M.; Bautista, F.; Meazza, C.; Janeway, K.; Dela Cruz, F. S.; Whittle, S.; Morgenstern, D. A.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

Minimally invasive surgery for abdominal and thoracic neuroblastic tumors: A systematic review by the APSA Cancer committee

Review

Gurria, J. P.; Malek, M. M.; Heaton, T. E.; Gehred, A.; Lautz, T. B.; Rhee, D. S.; Tracy, E. T.; Grant, C. N.; Baertshiger, R. M.; Bruny, J.; more...
Journal of Pediatric Surgery (2020)

Fulltext@MSK | Save

B7H3-directed intraperitoneal radioimmunotherapy with radioiodinated omburtamab for desmoplastic small round cell tumor and other peritoneal tumors: Results of a phase I study

Journal Article

Modak, S.; Zanzonico, P.; Grkovski, M.; Slotkin, E. K.; Carrasquillo, J. A.; Lyashchenko, S. K.; Lewis, J. S.; Cheung, I. Y.; Heaton, T.; LaQuaglia, M. P.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Reactive regional lymphadenopathy associated with neuroblastoma immunotherapy

Meeting Abstract

Lentini-Rivera, A.; Kushner, B.; Modak, S.; Price, A.
Pediatric Blood and Cancer (2020)

Fulltext@MSK | Save